Subcutaneous Amivantamab Cuts Infusion Time in NSCLC Care

Subcutaneous amivantamab (Rybrevant Faspro) injections can be administered in 5 minutes or less, compared with an infusion time of approximately 2 to 4 hours for intravenous amivantamab. In the phase 2 PALOMA-2 trial (NCT05498428), this shorter administration time applied to patients with treatment-naive, EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving subcutaneous amivantamab plus lazertinib (Lazcluze).

Misako Nagasaka, MD, PhD, an associate clinical professor in the Division of Hematology/Oncology at the University of California, Irvine (UCI), who presented the PALOMA-2 data at IASLC 2026 World Conference on Lung Cancer (WCLC), spoke with CancerNetwork^® about how much of a practical difference the subcutaneous formulation makes for patients and infusion center logistics. The use of subcutaneous amivantamab, she said, can open more infusion treatment slots in a given center, allowing practices to accompany more patients who may require chemotherapy or other intravenous agents.

Editor’s Note: Nagasaka declares that her personal opinions/thoughts are hers and not those of UCI Health, UC Regents, and any other related entities.

Transcript:

CancerNetwork: How much of a practical difference does the subcutaneous formulation of amivantamab make for patients and infusion center logistics in terms of tolerability?

Nagasaka: There is a huge difference. Injections only take 5 minutes or less, and even if you monitor the patient for their first injection, it’s going to be less than a few hours, whereas the intravenous formulation takes a much longer time to give, and that has been very inconvenient for patients. Less injection time means that we can treat more patients; we can accommodate more patients in the infusion suite, and that’s also very important because at some point we had times where patients had to wait because there wasn’t a new chemotherapy or new infusion treatment slot opening for the next several days, sometimes a week. But if the slots are much shorter to begin with, then multiple slots can be opened up for it, and that means many patients would be able to start earlier.

Reference

Nagasaka M, Dias JM, Tan J-L, et al. First-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC: updated results from the PALOMA-2 study. Presented at: 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract PT2.03.06.